We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Allergan (AGN) Shareholders Approve Acquisition by AbbVie
Read MoreHide Full Article
Allergan plc announced that its shareholders have approved its pending acquisition by AbbVie, Inc. (ABBV - Free Report) . Allergan said that approximately 68.6% of shareholders eligible to vote at Allergan’s extraordinary general meeting of shareholders as well as a special court-ordered meeting of shareholders voted in favor of the transaction.
Allergan announced the definitive transaction to be acquired by AbbVie in a cash-and-stock deal in June this year. AbbVie is offering $120.30 in cash and 0.866 of its share (worth $67.94) for each share of Allergan. The total transaction value is nearly $63 billion. The acquisition is expected to close by early 2020, if all necessary approvals are obtained.
Allergan’s share price has risen 26.4% this year so far against the industry’s decrease of 8.8%.
AbbVie’s offer represented a premium of 45% to Allergan’s closing price on Jun 24, thereby proving to be rewarding for its shareholders. Moreover, with blockbuster eye drug, Restasis expected to face generic competition, fears of new competition to Allergan’s key drug, Botox and some recent pipeline setbacks, the merger with AbbVie could prove to be the best way out for Allergan.
Meanwhile, AbbVie’s rationale behind the Allergan deal is to add a new blockbuster product to its portfolio, Botox, ahead of generic competition for its blockbuster inflammatory medicine, Humira. Generic versions of Humira are already denting revenues in Europe and are expected to be launched in the United States in 2023. AbbVie is heavily dependent on Humira and is looking to diversify its portfolio.
Approved for therapeutic and aesthetic use, Botox is a key top-line driver for Allergan and looks fit to be the next revenue driver for AbbVie after Humira loses exclusivity. Overall, the Allergan acquisition should diversify AbbVie’s revenue base to markets/categories outside AbbVie’s present drug portfolio and accelerate its non-Humira business.
However, after the deal was announced, some investors expressed concerns that AbbVie has overpaid for Botox as new competitive pressure looms large.
In February 2019, Evolus, Inc.’s (EOLS - Free Report) Jeuveau injection, indicated to improve the appearance of glabellar or frown lines, was approved by the FDA, which can pose competition to Botox. In the fall of 2019, Revance Therapeutics, Inc. (RVNC - Free Report) will file for approval of DaxibotulinumtoxinA for Injection (DAXI), a rival treatment to Botox for the frown lines indication. It has demonstrated longer duration of efficacy compared to Botox in late-stage studies.
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1% and +98.3%.
This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
Image: Bigstock
Allergan (AGN) Shareholders Approve Acquisition by AbbVie
Allergan plc announced that its shareholders have approved its pending acquisition by AbbVie, Inc. (ABBV - Free Report) . Allergan said that approximately 68.6% of shareholders eligible to vote at Allergan’s extraordinary general meeting of shareholders as well as a special court-ordered meeting of shareholders voted in favor of the transaction.
Allergan announced the definitive transaction to be acquired by AbbVie in a cash-and-stock deal in June this year. AbbVie is offering $120.30 in cash and 0.866 of its share (worth $67.94) for each share of Allergan. The total transaction value is nearly $63 billion. The acquisition is expected to close by early 2020, if all necessary approvals are obtained.
Allergan’s share price has risen 26.4% this year so far against the industry’s decrease of 8.8%.
AbbVie’s offer represented a premium of 45% to Allergan’s closing price on Jun 24, thereby proving to be rewarding for its shareholders. Moreover, with blockbuster eye drug, Restasis expected to face generic competition, fears of new competition to Allergan’s key drug, Botox and some recent pipeline setbacks, the merger with AbbVie could prove to be the best way out for Allergan.
Meanwhile, AbbVie’s rationale behind the Allergan deal is to add a new blockbuster product to its portfolio, Botox, ahead of generic competition for its blockbuster inflammatory medicine, Humira. Generic versions of Humira are already denting revenues in Europe and are expected to be launched in the United States in 2023. AbbVie is heavily dependent on Humira and is looking to diversify its portfolio.
Approved for therapeutic and aesthetic use, Botox is a key top-line driver for Allergan and looks fit to be the next revenue driver for AbbVie after Humira loses exclusivity. Overall, the Allergan acquisition should diversify AbbVie’s revenue base to markets/categories outside AbbVie’s present drug portfolio and accelerate its non-Humira business.
However, after the deal was announced, some investors expressed concerns that AbbVie has overpaid for Botox as new competitive pressure looms large.
In February 2019, Evolus, Inc.’s (EOLS - Free Report) Jeuveau injection, indicated to improve the appearance of glabellar or frown lines, was approved by the FDA, which can pose competition to Botox. In the fall of 2019, Revance Therapeutics, Inc. (RVNC - Free Report) will file for approval of DaxibotulinumtoxinA for Injection (DAXI), a rival treatment to Botox for the frown lines indication. It has demonstrated longer duration of efficacy compared to Botox in late-stage studies.
Allergan currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1% and +98.3%.
This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
See their latest picks free >>